Biomarkers and methods of diagnosis and treatment for recurrent implant failure

A biomarker and biological technology, applied in the field of in vitro fertilization-embryo implantation, can solve the limitations and changes of RIF diagnosis and treatment methods

Pending Publication Date: 2022-04-08
YIKON GENOMICS (SUZHOU) CO LTD +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these analyzes based on differentially expressed genes usually require endometrial biopsies to be obtained from patients at specific time points in the cycle; and the results of the analysis often...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biomarkers and methods of diagnosis and treatment for recurrent implant failure
  • Biomarkers and methods of diagnosis and treatment for recurrent implant failure
  • Biomarkers and methods of diagnosis and treatment for recurrent implant failure

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0248] In order to explore the relationship between luteinizing hormone and RIF, the periodic changes of serum levels of luteinizing hormone LH in RIF patients were detected, and compared with the periodic changes of LH levels in other IVF patients.

[0249] In the previous study, patients with secondary infertility caused by tubal factors alone, aged 25-36 years old (average 27.5±2.4), without a history of embryonic cessation, were selected, and no hormone drugs were used within three months. The LH value on the 3rd and 5th day after ovulation. The average LH level of the patient population on D3 was 7.63±3.49mIU / ml; the average LH level on D5 was 6.67±4.53mIU / ml, and did not show low LH levels in the luteal phase. In this embodiment, patients who underwent IVF-ET due to tubal factors alone were selected as controls.

[0250] In short, in this example, patients with a history of RIF were selected as the test group; at the same time, patients who underwent IVF-ET due to tubal...

Embodiment 2

[0261] For recurrent implantation failures with low LH serum levels in the luteal phase, a new luteal support regimen supplemented with the LH functional analogue HCG was given, and the relevant clinical treatment responsiveness of the patients was retrospectively observed. In this retrospective observational study, according to the previous dynamic observation of LH levels in RIF patients and tubal factor IVF patients, the serum LH level on D2 day of the luteal phase was ≤5 IU / L as one of the enrollment conditions.

[0262] All patients enrolled in this study were from the Sixth Medical Center of the General Hospital of the Chinese People's Liberation Army; and signed informed consent. All clinical studies were approved by the institutional ethics committee before being conducted.

[0263] A total of 84 patients were enrolled. The general health status of the patient is good, and there is no history of immunization, chromosomal abnormalities, and recurrent miscarriage; ,35(...

Embodiment 3

[0287] To examine the genetic basis of responsiveness to HCG luteal support therapy in RIF patients by whole-genome exome sequencing and functional enrichment analysis.

[0288] In this study, 10 patients were randomly selected from the RIF patients who achieved successful clinical pregnancy by using the HCG supplementary luteal phase support treatment regimen described in Example 2 as the case group. At the same time, 10 patients with RIF who had not been tested for LH hormone levels and received luteal support with HCG were randomly selected as the control group. All patients included in the study were from the Sixth Medical Center of the General Hospital of the Chinese People's Liberation Army; and signed informed consent. A comparison of patient characteristics between case and control groups is shown in Table 5.

[0289] Table 5 Comparison of general demographic characteristics of patients between the two groups

[0290]

[0291] Note: P<0.05 was regarded as statisti...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to methods of luteal support therapy for recurrent implantation failure, as well as methods and biomarkers for predicting the responsiveness of luteal support therapy for recurrent implantation failure patients.

Description

technical field [0001] The invention relates to the technical field of in vitro fertilization-embryo implantation. More specifically, the present invention relates to methods of luteal support therapy for recurrent implantation failures, and methods and biomarkers for predicting responsiveness to luteal support therapy in patients with recurrent implantation failures. Background technique [0002] Repeated implantation failure (RIF, repeated implantation failure) is a special type of disease in the field of assisted reproductive therapy (Bashiri A, Halper KI, Orvieto R. Recurrent Implantation Failure-update overview on etiology, diagnosis, treatment and future directions. Reproductive Biology and Endocrinology 2018;16:121). Generally, if a patient fails to obtain a clinical pregnancy after more than three consecutive cycles of high-quality embryo transfer, it is considered repeated implantation failure. RIF occurs in 10-15% of in vitro fertilization-embryo transfer (IVF-ET...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12Q1/6883G01N33/76G01N33/68A61K38/24A61P15/06A61K31/57A61K31/565
Inventor 郭翊明商微陆思嘉邹央云孙悦
Owner YIKON GENOMICS (SUZHOU) CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap